Skip to main content
Premium Trial:

Request an Annual Quote

Bruker to Pay $2.4M to Settle SEC Violations Related to China Business

NEW YORK (GenomeWeb) — The US Securities and Exchange Commission today charged Bruker with violating the Foreign Corrupt Practices Act.

The SEC charged that the Billerica, Mass.-based company provided non-business related travel and improper payments to Chinese government officials in an effort to win business.

Bruker has agreed to pay approximately $2.4 million to settle the charges, including $1,714,852 in disgorgement, $310,117 in prejudgment interest, and a $375,000 penalty.

An investigation by the agency found that Bruker lacked sufficient internal controls to prevent and detect roughly $230,000 in improper payments made out of its China-based offices. According to the SEC, the company's China-based offices falsely recorded these payments in their records as legitimate business and marketing expenses.

Bruker realized roughly $1.7 million in profits from sales contracts with state-owned entities in China whose officials received the improper payments, the SEC said. It added that Bruker self-reported the misconduct and provided "extensive cooperation" during the SEC's investigation. 

The company has consented to the order without admitting or denying the SEC findings.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.